top of page
  • Trial Update

NCT03940833: Phase 1/2: Adoptive BCMA CAR-NK Cells - RRMM

Updated: May 26, 2022

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

BCMA CAR-NK Cells


The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.


Asclepius Technology Company Group (Suzhou) Co., Ltd.


Chinese study


Department of Hematology, Wuxi People's Hospital, Nanjing Medical University

Wuxi, Jiangsu, China, 214000


BCMA CAR-NK 92 cells

 

ClinicalTrials.gov Identifier: NCT03940833


First Posted : May 7, 2019

 

allogeneic natural killer cell line NK-92

haNK

NK-92

NK-92 cells

 

Location

China






תגובות


Posts Archive
bottom of page